Clarifying the PSA grey zone: The management of patients with a borderline PSA

No abstract is available for this paper.

• Publication year

  2016

• Venue

  International journal of clinical practice

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ijcp.12883PMID 27672001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI‐transrectal ultrasonography (TRUS) fusion‐guided transperineal prostate biopsies as a validation tool

  2016cited by this paper
• European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi‐institutional study

  2016cited by this paper
• The percentage of prostate‐specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years

  2016cited by this paper
• Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer

  2016cited by this paper
• Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort

  2016cited by this paper
• The effect of bicycling on PSA levels: a systematic review and meta-analysis

  2015cited by this paper
• Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

  2015cited by this paper
• Prostate cancer and the PCP: the screening dilemma

  2015cited by this paper
• The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

  2015cited by this paper
• Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

  2015cited by this paper
• Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

  2015cited by this paper
• Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies

  2015cited by this paper
• Prostate cancer screening in Primary Health Care: the current state of affairs

  2015cited by this paper
• Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists

  2015cited by this paper
• Magnetic resonance imaging-targeted vs. conventional transrectal ultrasound-guided prostate biopsy: single-institution, matched cohort comparison.

  2015cited by this paper
• First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer

  2015cited by this paper
• Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results.

  2015cited by this paper
• PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml-1 and 10.1–20.0 ng ml-1: a multicenter study

  2014cited by this paper
• Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.

  2014cited by this paper
• The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation.

  2014cited by this paper
• Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

  2014cited by this paper
• Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.

  2014cited by this paper
• Magnetic resonance spectroscopy imaging‐directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate‐specific antigen between 4–10 ng/mL and normal digital rectal examination

  2014cited by this paper
• Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases

  2014cited by this paper
• Impact of obesity on the predictive accuracy of prostate‐specific antigen density and prostate‐specific antigen in native Korean men undergoing prostate biopsy

  2014cited by this paper
• PSA density improves prediction of prostate cancer.

  2014cited by this paper
• Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

  2014cited by this paper
• Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.

  2014cited by this paper
• Measuring the impact of our methodological research at the UK Medical Research Council Clinical Trials Unit

  2013cited by this paper
• A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

  2013cited by this paper
• Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.

  2013cited by this paper
• From prostate‐specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer

  2013cited by this paper
• The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

  2013cited by this paper
• Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range

  2013cited by this paper
• Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study

  2013cited by this paper
• Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  2012cited by this paper
• Risk-based prostate cancer screening.

  2012cited by this paper
• Head‐to‐head comparison of two online nomograms for prostate biopsy outcome prediction

  2011cited by this paper
• Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort

  2011cited by this paper
• An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cited by this paper
• Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone

  2011cited by this paper
• Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

  2011cited by this paper
• Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

  2009cited by this paper
• A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy

  2008cited by this paper
• Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.

  2007cited by this paper
• Characteristics of prostate cancer detected by digital rectal examination only.

  2006cited by this paper
• Race‐specific reference ranges of serum prostate‐specific antigen levels in countries with a low incidence of prostate cancer

  2006cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.

  2005cited by this paper
• Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

  2005cited by this paper
• Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

  2004cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

  2004cited by this paper
• Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

  2004cited by this paper
• Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

  2002cited by this paper
• Treatment of chronic prostatitis lowers serum prostate specific antigen.

  2002cited by this paper
• Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer

  2001cited by this paper
• Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.

  2000cited by this paper
• Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

  1999cited by this paper
• Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate‐specific antigen and transrectal ultrasonography

  1999cited by this paper
• Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer.

  1999cited by this paper
• Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer.

  1998cited by this paper
• Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer

  1998cited by this paper
• Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

  1997cited by this paper
• Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.

  1996cited by this paper
• Age-specific reference ranges for serum prostate-specific antigen in black men.

  1996cited by this paper
• Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

  1996cited by this paper
• Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.

  1996cited by this paper
• Ejaculation increases the serum prostate-specific antigen concentration.

  1996cited by this paper
• Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

  1995cited by this paper
• Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

  1995cited by this paper
• Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.

  1995cited by this paper
• Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

  1995cited by this paper
• Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

  1994cited by this paper
• Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

  1994cited by this paper
• Racial differences in adenocarcinoma of the prostate in North American men.

  1994cited by this paper
• The clinical usefulness of prostate specific antigen: update 1994.

  1994cited by this paper
• COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE CANCER: RESULTS OF A MULTICENTER CLINICAL TRIAL OF 6,630 MEN

  1994cited by this paper
• Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

  1994cited by this paper
• Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

  1993cited by this paper
• Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration.

  1993cited by this paper
• Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

  1993cited by this paper
• Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

  1991cited by this paper
• Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

  1988cited by this paper

• miR-191-5p: A tumour suppressor miRNA and a personalized biomarker and potential therapeutic tool connecting prostate cancer and obesity.

  2025cites this paper
• Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO)

  2025cites this paper
• The Association Between Borderline Personality Disorder Symptoms and Social Behaviour Among University Students

  2025cites this paper
• Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study

  2025cites this paper
• Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

  2024cites this paper
• Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers

  2023cites this paper
• Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients

  2023cites this paper
• Carbon nanomaterials-based electrochemical cancer biomarkers biosensors

  2022cites this paper
• Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool

  2022cites this paper
• Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis

  2022cites this paper
• Role of glutathione-S-transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate-specific antigen values

  2022cites this paper
• MiRNA biomarkers in cancers of the male reproductive system: Are we approaching clinical application?

  2022cites this paper
• A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation

  2022cites this paper
• Prostate Imaging Reporting and Data System score (PI-RADS) and Glutathione S-transferase P1 methylation status (GST-P1) in the diagnosis of prostate cancer patients with borderline PSA values

  2022cites this paper
• MIL-88B(Fe)-reduced graphene oxide as an artificial enzyme for gold nanorod etching and its application to develop the prostate-specific antigen immunosensor

  2022cites this paper
• Profiling the proteoforms of urinary prostate-specific antigen by capillary electrophoresis - mass spectrometry.

  2021cites this paper
• Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients

  2021cites this paper
• Spotlight on PSMA as a new theranostic biomarker for bladder cancer

  2021cites this paper
• Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis

  2021cites this paper
• In1-ghrelin splicing variant as a key element in the pathophysiological association between obesity and prostate cancer.

  2021cites this paper
• Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations

  2021cites this paper
• Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA

  2021cites this paper
• Correlation of Prostate-Imaging Reporting and Data Scoring System scoring on multiparametric prostate magnetic resonance imaging with histopathological factors in radical prostatectomy material in Turkish prostate cancer patients: a multicenter study of the Urooncology Association

  2020cites this paper
• Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples

  2020cites this paper
• Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.

  2020cites this paper
• A Comparative Study: Has MRI-guided Fusion Prostate Biopsy Changed the Prostate-specific Antigen Gray-zone Range?

  2019cites this paper
• Diagnostic and Prognostic Value of Monocarboxylate Transporters Gene Expression in Patients with Prostate Cancer and Its Potential Use in Liquid Biopsies: A Preliminary Study

  2019cites this paper
• PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

  2018cites this paper
• Carbon nanotubes-based electrochemical (bio)sensors for biomarkers

  2017cites this paper